Navigation Links
Cell Therapeutics Announces 2014 Outlook and Recent Drug Portfolio Progress
Date:1/13/2014

SEATTLE, Jan. 14, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced a corporate update for 2014 in addition to an overview of recent progress for its drug portfolio.

"We ended 2013 and have entered 2014 with a series of successes, including a global strategic partnership for pacritinib, positive reimbursement rulings in England/Wales and Germany for PIXUVRI, the reacquisition of rights to PIXUVRI and Opaxio in order to allow us to more efficiently move these programs forward and new positive interim data for tosedostat," said James A. Bianco, M.D. President and CEO of CTI. "We expect to continue that momentum with completion of the first of two Phase 3 clinical trials of pacritinib in myelofibrosis and potential topline data later in the year."

Progress Update

Pacritinib

  • In November 2013, CTI entered into a worldwide license agreement with Baxter International, Inc. (Baxter) to develop and commercialize pacritinib in which CTI and Baxter will jointly commercialize pacritinib in the United States and Baxter has exclusive commercialization rights for all indications outside the U.S.
  • The Phase 3 PERSIST-1 trial evaluating a broad set of myelofibrosis patients without limitations on blood platelet counts is currently enrolling patients. CTI expects to report topline data in the second half of 2014.
  • A second Phase 3 trial, PERSIST-2, in myelofibrosis patients with low platelet counts is expected to begin enrollment imminently. In October 2013, CTI reached agreement with the United States Food and Drug Administration (FDA) on a Special Protocol Assessment for this trial. This trial together with PERSIST-1 is intended to support registration in the U.S. and the Europea
    '/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Provides an Update on Anticipated Milestones for 2014 at the 32nd Annual J. P. Morgan Healthcare Conference
2. Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics
3. ImmunoCellular Therapeutics Provides Update on 2014 Corporate Strategies and Milestones
4. Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
5. Cell Therapeutics Reaches Agreement to Reacquire Rights to Two Anti-Cancer Compounds
6. Sorrento Therapeutics to Present at the Biotech Showcase 2014 and the 7th Annual OneMed Forum SF2014 in San Francisco
7. PhaseRx Appoints Michael Houston, Ph.D., Vice President, Therapeutics Development
8. ImmunoCellular Therapeutics Issues Shareholder Letter Providing Update on ICT-107 Program in Newly Diagnosed Glioblastoma
9. Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
10. Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
11. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... The scientific team of a new ... the leading academics in the field of aging Prof. ... life extension for model animals - 10 fold for nematodes) ... age-related diseases, primarily, around the stability and stress resistance of ... as "Stability analysis of a model gene network links aging, ...
(Date:8/28/2015)... and PITTSBURGH , ... MYL ) today announced that its shareholders have ... (NYSE: PRGO ; TASE) and the related ... at an extraordinary general meeting of shareholders held ... votes cast at the extraordinary general meeting. In ...
(Date:8/28/2015)... SAN FRANCISCO , August 28, 2015 ... is expected to reach USD 49.12 billion by 2020, ... 2020, according to a new report by Grand View ... an estimated CAGR of 49.7% from 2014 to 2020. ... Growing aging population along with rising incidences of ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5
... 2011  Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today ... edoxaban, a direct oral once-daily Factor Xa inhibitor, significantly ... total knee or hip arthroplasty, when compared to enoxaparin. ... composite of deep vein thrombosis (DVT) and pulmonary embolism ...
... SHANGHAI, Dec. 12, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: ... medical-device research and development outsourcing company with operations in ... of its fifth Life Science and Chemistry Awards, held ... Beijing. The theme of this year,s awards ...
Cached Medicine Technology:Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 2Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 3Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 4Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 5WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards 2WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards 3
(Date:8/30/2015)... ... , ... Scientists in France say asbestos exposure may put workers at higher ... has just posted an article on the new research. Click here to read ... among 2,024 French asbestos plant workers from 1978 to 2009. In addition to mesothelioma, ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, 2015 , ... ... and InHealth Media. Nutritional Products International and InHealth media is a global sales ... , “We are extremely pleased to continue our business relationship with Mr. Reid ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... Ultrasound (HIFU) medical devices for the treatment of prostate cancer, has announced the ... this summer at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® ...
(Date:8/29/2015)... ... August 30, 2015 , ... ... — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple ... digital handwritten signature. , Clinical trial sites can now use audio, ...
(Date:8/29/2015)... PA (PRWEB) , ... August 29, 2015 , ... ... due to insufficient scrotal support and protection against dribbled urine and sweat. "In ... from Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides ...
Breaking Medicine News(10 mins):Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2
... boost patient compliance, outcomes, researchers say , , THURSDAY, April ... moxifloxacin in combination with other drugs could cut several ... cure patients with drug-treatable tuberculosis, according to a phase ... patients failing to complete their drug therapy, so a ...
... A Trumbull, Conn., resident who was involved in ... conspiring to defraud the Internal Revenue Service (IRS), the ... in U.S. District Court in Manhattan to conspiracy to ... 2000 and February 2005, Koczon conspired with others to ...
... highlights accomplishments of three highly recruited adapted sports athletesGOLDEN ... and resource center Courage Center has had a history ... adapted sports such as wheelchair basketball and rugby. On ... school seniors will sign college letters of intent in ...
... the image and information management marketBOSTON, April 2 ... in radiology and medical image and information management solutions, ... Emageon Inc. (Nasdaq: EMAG ). (Logo: ... Emageon have a shared vision that is focused on ...
... the release of the first long-range plan for tackling ... Americans each year. , Opportunities and Challenges in Digestive ... Diseases describes the impact of diseases ranging from foodborne ... priorities for research over the next 10 years. The ...
... The Kennedy Krieger Institute will commemorate the two-year ... www.IANProject.org , with the much-anticipated launch of its ... a more user-friendly, easily navigated online community. Launched ... registry, the IAN Project has become the largest ...
Cached Medicine News:Health News:New Antibiotic Could Shorten TB Treatment 2Health News:Connecticut Resident Pleads Guilty to Multi-Million Dollar Tax Fraud Conspiracy Involving New York City Hospital 2Health News:Courage Center Hosts College Scholarship Signing Ceremony Thursday, April 9, 2009 2Health News:AMICAS Announces Completion of Merger with Emageon 2Health News:AMICAS Announces Completion of Merger with Emageon 3Health News:AMICAS Announces Completion of Merger with Emageon 4Health News:NIH releases the first research plan to reduce the burden of digestive diseases 2Health News:NIH releases the first research plan to reduce the burden of digestive diseases 3Health News:Interactive Autism Network opens its doors to adults with autism 2Health News:Interactive Autism Network opens its doors to adults with autism 3
... drainage set (EVD set) drains ... external ventricular drainage. It can ... a ventricular catheter or with ... from the Aesculap Spiegelberg ICP, ...
... The CODMAN EDS 3 CSF External Drainage ... 200 nurses and physicians. The clinicians who work ... distinguish the CODMAN EDS 3: ease-of-use in an ... SPLASHFREE valve, accurate hydrostatic leveling from a ...
Monitorr ICP external CSF drainage system with self-contained ICP setting....
Monitorr ICP external CSF drainage and monitoring system with patient line one way valve....
Medicine Products: